The complete longevity protocol guide for Australians: peptides, supplements, and biological age

Longevity medicine has evolved significantly from vague wellness claims into a data-driven discipline with specific, measurable targets. The field distinguishes between chronological age (years lived) and biological age (the functional state of your cells and tissues, measured via epigenetic clocks, telomere length, and biomarker panels). The goal of longevity medicine is not to simply extend lifespan but to extend healthspan — the period of life lived with full physical and cognitive function. The most credible longevity practitioners (Peter Attia, David Sinclair, Rhonda Patrick) emphasise that the interventions with the strongest evidence for extending healthspan are not exotic peptides but foundational behaviours: VO2 max training, resistance exercise, sleep quality, protein intake, and social connection. Peptides and supplements are optimisers applied on top of this foundation — not substitutes for it.

The 2013 Lopez-Otin paper identified nine hallmarks of ageing — cellular mechanisms whose progressive deterioration drives the ageing phenotype. These include telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Longevity peptides intervene at specific points in this framework. Epithalon directly activates telomerase — the enzyme that repairs telomere shortening. NMN restores NAD+ availability, which supports SIRT1 and SIRT3 sirtuins (deregulated nutrient sensing). GH secretagogues like Ipamorelin/CJC-1295 restore physiological GH pulsatility, which declines with age and contributes to impaired proteostasis and body composition deterioration. GHK-Cu promotes collagen and elastin synthesis and activates repair gene expression (altered intercellular communication). Understanding which hallmark each intervention targets allows for more intelligent protocol design.

The age-related decline in growth hormone secretion (somatopause) is one of the most consistently documented features of biological ageing. GH peaks in adolescence and declines approximately 14% per decade from the mid-twenties. By age 60, most individuals are secreting less than 25% of their peak GH levels. The consequences of this decline include reduced lean mass, increased visceral fat, impaired sleep architecture, reduced collagen synthesis, impaired immune function, and reduced cognitive performance. Ipamorelin and CJC-1295 restore physiological GH pulsatility by stimulating the pituitary to release GH in a pattern that mimics natural secretion — pulsatile, with peak release during deep sleep. Unlike exogenous growth hormone (which is TGA-approved only for diagnosed GH deficiency), GH secretagogues are not providing external GH — they are restoring the body's own secretion. This distinction is important both for safety (the pituitary's feedback mechanisms remain intact) and for regulatory accessibility.

NAD+ (nicotinamide adenine dinucleotide) is the central coenzyme of cellular metabolism — involved in over 500 enzymatic reactions and critical for mitochondrial energy production, DNA repair, and sirtuin activation. NAD+ levels decline approximately 50% between the ages of 20 and 60, and this decline is now understood to be a primary driver of the metabolic features of ageing. NMN (nicotinamide mononucleotide) is a direct precursor to NAD+ — oral NMN supplementation has been consistently demonstrated to raise blood NAD+ levels in human trials. Harvard's David Sinclair takes NMN daily and has been the most prominent advocate for NAD+ restoration as a longevity intervention. Australian-based clinical trials at the University of Washington and others have confirmed the safety and efficacy of NMN at doses of 250 mg to 1.25 g daily. NMN is available without prescription in Australia and represents the most accessible and evidence-supported longevity supplement on the market.

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson. It represents the most direct known pharmacological intervention targeting telomere biology — the molecular clock of cellular ageing. Epithalon stimulates the pineal gland and directly activates telomerase, the enzyme responsible for maintaining and repairing telomere length. In animal studies, Epithalon treatment has been associated with significant telomere lengthening and measurable lifespan extension. Human observational data from elderly populations shows improved melatonin secretion, immune function, and reduced incidence of age-related disease in Epithalon-treated groups compared to controls. The dosing protocol is unusual: Epithalon is not taken daily but in concentrated courses (5–10 mg daily for 10–20 days) once or twice per year. In Australia, it is classified as research-use only and requires medical supervision.

Longevity protocols without measurement are lifestyle preferences, not medicine. The minimum biomarker panel for anyone serious about longevity should include: IGF-1 (GH axis function), testosterone (total and free), DHEA-S (adrenal reserve), fasting glucose and HbA1c (metabolic health), high-sensitivity CRP (systemic inflammation), lipid panel with ApoB (cardiovascular risk), homocysteine (methylation and cardiovascular), omega-3 index, 25-OH vitamin D, and basic metabolic panel. Advanced practitioners add epigenetic age testing (Horvath clock or GrimAge) to measure biological age directly — a more precise target than any individual biomarker. Retesting every 6–12 months allows you to assess whether your protocol is actually improving these markers, which is ultimately the only meaningful measure of whether a longevity intervention is working for your specific biology.